IMMX
Immix Biopharma Inc.
$7.07
-$0.31(-4.20%)
68
Overall
60
Value
100
Tech
44
Quality
Market Cap
$47.13M
Volume
1.55M
52W Range
$1.34 - $7.73
Target Price
$8.00
Company Overview
| Mkt Cap | $47.13M | Price | $7.07 |
| Volume | 1.55M | Change | -4.20% |
| P/E Ratio | -2.2 | Open | $7.50 |
| Revenue | -- | Prev Close | $7.38 |
| Net Income | $-21.6M | 52W Range | $1.34 - $7.73 |
| Div Yield | N/A | Target | $8.00 |
| Overall | 68 | Value | 60 |
| Quality | 44 | Technical | 100 |
No chart data available
About Immix Biopharma Inc.
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and immune-dysregulated diseases in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and colorectal cancer; and NXC-201 for relapsed/refractory multiple myeloma. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
Latest News
Immix Biopharma Enters Underwriting Agreement with Morgan Stanley
TipRanks Auto-Generated Newsdesk•5 days ago
Immix Biopharma Announces Positive Phase 2 Trial Results
TipRanks Auto-Generated Newsdesk•6 days ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | IMMX | $7.07 | -4.2% | 1.55M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |